EQS-Adhoc: Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures
|
EQS-Ad-hoc: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Preliminary Results Berlin, 17 January 2023. According to preliminary, unaudited figures, Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) is expected to achieve a Group net profit of roughly EUR 30 million and Group sales of around EUR 225 million for the 2022 financial year. The result is thus expected to be around 10% higher than the figures forecasted in July 2022 of around EUR 27 million for Group net profit and around EUR 200 million for Group sales. The audited full annual financial statements for the FY 2022 are scheduled to be published on 30 March 2023. For enquiries please contact:
17-Jan-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-112 |
| E-mail: | [email protected] |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1536993 |
| End of Announcement | EQS News Service |
|
|
1536993 17-Jan-2023 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie
Eine klare Neigung zu Buy-Einschätzungen bei Eckert & Ziegler Strahlen- und Medizintechnik AG, ohne Sell-Einschätzungen.
Das Kursziel von 95 € für Eckert & Ziegler Strahlen- und Medizintechnik AG bedeutet eine deutliche Steigerung von über 50% gegenüber dem aktuellen Kurs von 48.7 €.
